The studies claim that blocking the interaction between the virus and NRP1 could give a way to combat coronavirus infection. No one faults the doctors who initially tried HCQ out, when we had no idea what treatments would work. The problem is that some individuals (see, e.g., earlier in this thread) insist upon pushing it as cure long after the evidence has drop pretty strongly against it.
He is an Explorer-At-Large at the National Geographic Society, Commissioner for the U.S. Commission on Ocean Policy, and a Research Scholar at the Woods Hole Oceanographic Institution. Navy for more than 30 years and continues to utilize the Office of Naval Research. A pioneer in the introduction of deep-sea submersibles and remotely operated vehicle systems, he has taken part in more than 155 deep-sea expeditions.
IV medications are usually administered by hospital staff, so there is certainly little chance it won’t get. It is type of significant that in the US HCQ fanboys protest that HCQ wouldn’t normally work in trials without zinc, while in France, they protest that HCQ cannot work without Azithromycin. But, really, because of methodology, insufficient clinical controls, verification, or followup, Boulware’s study is a tale.
It’s worth noting that the Brazil study that was roundly criticized for giving toxic doses of chloroquine to patients never exceeded 1.2 grams each day. Through contrast, RECOVERY gave 2.4 grams the first day. Oh for crying out loud, you are twisting my words so they come out backwards… Have you been in the common practice of taking medication you don’t need? If it was a good treatment for a condition I had fashioned, or easily was enrolled in a clinical trial, I would take it. Hcq was investigated in early stages because of in vitro antiviral effects , and previous hints of efficacy vs SARS as well as similar results vs COV2 out of China.
Boulware poisoned the well by separating benefits to be able to lessen significance. Skipper poisoned the well by claiming early treatment when actually treatment was given beyond the antiviral window-to low risk participants. Derek and I probably agree that up to now data for single-drug anti-viral treatment of Covid-19 shows modest effects. That greatly complicates attempts at RCTs in this pandemic and makes blanket statements about efficacy inappropriate.